Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CRME

Cardiome Pharma (CRME) Stock Price, News & Analysis

Cardiome Pharma logo

About Cardiome Pharma Stock (NASDAQ:CRME)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$2.30
$2.45
50-Day Range
N/A
52-Week Range
$1.29
$4.84
Volume
90,444 shs
Average Volume
135,322 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Remove Ads
Receive CRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiome Pharma and its competitors with MarketBeat's FREE daily newsletter.

CRME Stock News Headlines

Brace Yourself for Jeff Bezos’ “Amazon Helios”
Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical technology that could change society forever and make early investors rich.
See More Headlines

CRME Stock Analysis - Frequently Asked Questions

Cardiome Pharma Corp (NASDAQ:CRME) released its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biopharmaceutical company earned $6.54 million during the quarter, compared to the consensus estimate of $7.34 million.

Company Calendar

Last Earnings
5/15/2018
Today
4/04/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CRME
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NASDAQ:CRME) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners